Startups
Follow us on Twitter: @evoke_group
Interested in a career with us? Visit: https://www.evokegroup.com/careers/
Interested in a career with us? Visit: https://www.evokegroup.com/careers/
Overview
Location
United States, North Carolina, Cary
Employees
1001-5000
Phone
+1 212-228-7200
Founded date
1994
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 5, 2023 | eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update | /EIN News/ -- Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerabilit... |
| Jan 4, 2023 | Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program | Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B... |
| Oct 31, 2022 | eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences | /EIN News/ -- SAN DIEGO and REDWOOD CITY, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer,... |
| Oct 26, 2022 | eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 | Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023 /EIN News/ -- SAN DIEGO and REDWOOD CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NA... |
| Oct 26, 2022 | eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 | SAN DIEGO and REDWOOD CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announc... |
| Sep 20, 2022 | Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159 | Expansion study will evaluate PY159, an anti-TREM1 antibody, as a monotherapy and in combination with pembrolizumab in patients with selected prespecified tumor histologies |
| Sep 14, 2022 | eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 | - Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 - - Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation - SAN DIEGO and REDWOOD CI... |
| Sep 6, 2022 | eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference | SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announce... |
| Sep 20, 2021 | Experts Call on World Leaders to Commit to a Global Plan of Attack on COVID at Summit | More Than 60 Leading Organizations Across Civil Society, Academia, Philanthropy, Health, and Social Enterprise Define a 6-Point Plan to End the Global COVID-19 Crisis SEATTLE, Sept. 20, 2021 /PRNewswire/ -- This week, hosted by the United S... |
Show more
Reviews 0
FAQ about Evoke
When was Evoke founded?
Evoke was founded in 1994.
What has the press written about Evoke?
Parsers VC has collected 14 articles mentioning Evoke, among them “eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update” (Jan 5, 2023) and “Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program” (Jan 4, 2023).
Is Evoke still active?
Yes, Evoke is active; its latest activity on Parsers VC dates from May 11, 2023.